バーチャル臨床試験市場：研究設計、関連別-世界予測2025～2030年

バーチャル臨床試験市場は、2023年に38億1,000万米ドルと評価され、2024年には46億6,000万米ドルに達すると予測され、CAGR 22.44％で成長し、2030年には157億2,000万米ドルになると予測されています。

バーチャル臨床試験（VCTs）は、臨床研究における革新的なアプローチであり、臨床試験実施の伝統的側面をデジタルツールやプラットフォームで補完または代替し、遠隔地からの参加やデータ収集を可能にするものです。VCTの必要性は、参加者の多様性を高め、コストを削減し、患者のアクセス性とコンプライアンスを改善する必要性から生じる。特に患者中心のデータ収集が最重要となる医薬品・治療法開発の様々な段階で応用されています。主要エンドユーザーには、製薬会社、バイオテクノロジー企業、業務の効率化と幅広い層へのリーチを目指す受託研究機関などが含まれます。

市場洞察によると、デジタルヘルス革新の急増と遠隔医療の受け入れ拡大が成長に大きく影響しています。ウェアラブル技術、AI、機械学習などの進歩がVCTの効率化と個別化を促進し、調試験における実世界エビデンスのさらなる統合の機会を開いています。企業は、先進的データ管理ソリューションに投資し、進化する規制基準へのコンプライアンスを確保することで、こうした進歩を活用しています。しかし、データプライバシーの懸念、技術的な偏り、国際的な規制の違いなど、普及の妨げとなりうる限界もあります。また、地域によってはインフラが整備されておらず、人口動態の違いによるデジタルデバイドも大きな課題となっています。

ビジネス成長のためのイノベーションセグメントとしては、分散型臨床試験用の安全なプラットフォームの開発、デジタル患者募集戦略の強化、データセキュリティのためのブロックチェーンの活用などが挙げられます。予測分析や患者モニタリングにおけるAIの役割に関する調試験も有望です。市場力学は急速な技術進歩を特徴としており、効果的な市場浸透のためには機敏な戦略とパートナーシップが必要です。企業は、製品イノベーションを推進するためにハイテク企業との協力関係を築くことに注力すべきであり、VCTにとって有利な状況を形成するために規制機関と関わるべきです。全体として、プライバシーや規制上の課題に対処しながら、患者中心のイノベーションを活用することが、バーチャル臨床試験の持続的な成長と成功には不可欠です。

市場力学：急速に進化するバーチャル臨床試験市場における主要市場洞察の解明

バーチャル臨床試験市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 遠隔医療の採用拡大
  • 医療セグメントにおけるデジタル化の世界の導入拡大
  • 有利な政府支援と相まって研究開発活動が活発化
• 市場抑制要因
  • 大規模なデータ収集、データの正確性と信頼性、技術的障害に対する懸念
• 市場機会
  • 臨床試験における新技術の統合
  • ソフトウェア、バイオテクノロジー、臨床研究企業間の協力関係の構築
• 市場課題
  • 被験者登録と参加活動に伴う煩雑で困難なプロセス

ポーターのファイブフォース：バーチャル臨床試験市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バーチャル臨床試験市場における外部からの影響の把握

外部マクロ環境要因は、バーチャル臨床試験市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調試験することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：バーチャル臨床試験市場における競合情勢の把握

バーチャル臨床試験市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：バーチャル臨床試験市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バーチャル臨床試験市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：バーチャル臨床試験市場における成功への道筋を描く

バーチャル臨床試験市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調試験手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遠隔医療の導入増加
    • 医療セグメントではデジタル化の導入が世界的に拡大
    • 研究開発活動の急増と政府の好意的な支援
  • 抑制要因
    • 大規模なデータ収集、データの正確性と信頼性、技術的な失敗に関する懸念
  • 機会
    • 臨床試験における新技術の統合
    • ソフトウェア、バイオテクノロジー、臨床研究試験企業間の新たなコラボレーション
  • 課題
    • 登録やエンゲージメント活動に伴う煩雑で困難なプロセス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 バーチャル臨床試験市場：研究設計別

• イントロダクション
• 拡大アクセス試験
• 介入試験
• 観察試験

第7章 バーチャル臨床試験市場：関連別

• イントロダクション
• 心血管疾患
• 腫瘍

第8章 南北アメリカのバーチャル臨床試験市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋のバーチャル臨床試験市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのバーチャル臨床試験市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AiCure, LLC
• Clinical Ink, Inc. by GI Partners
• CliniOps, Inc
• Everest Global, Inc
• ICON PLC
• IQVIA Inc.
• Medable, Inc.
• Medidata Solutions by Dassault Systemes S.E.
• Medpace, Inc.
• MedPoint Digital, Inc.
• Navitas Inc.
• Oracle Corporation
• Parexel International Corporation
• Pfizer Inc.
• VirTrial, LLC by Signant Health

LIST OF FIGURES

• FIGURE 1. VIRTUAL CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. VIRTUAL CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. VIRTUAL CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. VIRTUAL CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VIRTUAL CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VIRTUAL CLINICAL TRIALS MARKET DYNAMICS
• TABLE 7. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. CANADA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 22. CANADA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CHINA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 34. CHINA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. INDIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 36. INDIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. ITALY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 71. ITALY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. POLAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 79. POLAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. QATAR VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 81. QATAR VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM VIRTUAL CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM VIRTUAL CLINICAL TRIALS MARKET SIZE, BY IMPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIRTUAL CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. VIRTUAL CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

The Virtual Clinical Trials Market was valued at USD 3.81 billion in 2023, expected to reach USD 4.66 billion in 2024, and is projected to grow at a CAGR of 22.44%, to USD 15.72 billion by 2030.

Virtual clinical trials (VCTs) are innovative approaches in clinical research where the traditional aspects of trial conduction are complemented or replaced by digital tools and platforms, enabling remote participation and data collection. The necessity for VCTs arises from the need to enhance participant diversity, reduce costs, and improve patient accessibility and compliance, especially pertinent during global events like pandemics where physical distancing is vital. They find application in numerous phases of drug and therapy development, particularly where patient-centric data collection is paramount. Key end-users include pharmaceutical companies, biotechnology firms, and contract research organizations aiming to streamline operations and reach broader demographics.

Market insights reveal a surge in digital health innovations and an increasing acceptance of telemedicine, significantly influencing growth. Factors such as advancements in wearable technology, AI, and machine learning are driving efficiencies and personalization in VCTs, opening up opportunities for further integration of real-world evidence in research. Companies are capitalizing on these advancements by investing in sophisticated data management solutions and ensuring compliance with evolving regulatory standards. However, limitations include data privacy concerns, technological biases, and varying international regulations that could hinder widespread adoption. The lack of infrastructure in certain regions and the digital divide between different demographic groups pose significant challenges.

For business growth, areas of innovation include development of secure platforms for decentralized trials, enhancement of digital patient recruitment strategies, and leveraging blockchain for data security. Research into AI's role in predictive analytics and patient monitoring is also promising. Market dynamics are characterized by rapid technological advancements, which necessitate agile strategies and partnerships for effective market penetration. Companies should focus on forging collaborations with tech firms to drive product innovation, and engage with regulatory bodies to shape favorable landscapes for VCTs. Overall, tapping into patient-centric innovations while addressing privacy and regulatory challenges will be crucial for the sustained growth and success of virtual clinical trials.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Virtual Clinical Trials Market

The Virtual Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing adoption of telehealth
  • Growing adoption of digitization in healthcare sector globally
  • Proliferation in research and development activities coupled with favorable government support
• Market Restraints
  • Concerns over large data collection, data accuracy and reliability, and technological failure
• Market Opportunities
  • Integration of new technologies in clinical trials
  • Emerging collaborations between software, biotechnology and clinical research companies
• Market Challenges
  • Cumbersome and difficult process with enrolment and engagement activities

Porter's Five Forces: A Strategic Tool for Navigating the Virtual Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Virtual Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Virtual Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Virtual Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Virtual Clinical Trials Market

A detailed market share analysis in the Virtual Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Virtual Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Virtual Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Virtual Clinical Trials Market

A strategic analysis of the Virtual Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Virtual Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Clinical Ink, Inc. by GI Partners, CliniOps, Inc, Everest Global, Inc, ICON PLC, IQVIA Inc., Medable, Inc., Medidata Solutions by Dassault Systemes S.E., Medpace, Inc., MedPoint Digital, Inc., Navitas Inc., Oracle Corporation, Parexel International Corporation, Pfizer Inc., and VirTrial, LLC by Signant Health.

Market Segmentation & Coverage

This research report categorizes the Virtual Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Study Design, market is studied across Expanded Access Trials, Interventional Trials, and Observational Trials.
• Based on Implication, market is studied across Cardiovascular Disease and Oncology.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of telehealth
    • 5.1.1.2. Growing adoption of digitization in healthcare sector globally
    • 5.1.1.3. Proliferation in research and development activities coupled with favorable government support
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns over large data collection, data accuracy and reliability, and technological failure
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of new technologies in clinical trials
    • 5.1.3.2. Emerging collaborations between software, biotechnology and clinical research companies
  • 5.1.4. Challenges
    • 5.1.4.1. Cumbersome and difficult process with enrolment and engagement activities
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Virtual Clinical Trials Market, by Study Design

• 6.1. Introduction
• 6.2. Expanded Access Trials
• 6.3. Interventional Trials
• 6.4. Observational Trials

7. Virtual Clinical Trials Market, by Implication

• 7.1. Introduction
• 7.2. Cardiovascular Disease
• 7.3. Oncology

8. Americas Virtual Clinical Trials Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Virtual Clinical Trials Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Virtual Clinical Trials Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AiCure, LLC
• 2. Clinical Ink, Inc. by GI Partners
• 3. CliniOps, Inc
• 4. Everest Global, Inc
• 5. ICON PLC
• 6. IQVIA Inc.
• 7. Medable, Inc.
• 8. Medidata Solutions by Dassault Systemes S.E.
• 9. Medpace, Inc.
• 10. MedPoint Digital, Inc.
• 11. Navitas Inc.
• 12. Oracle Corporation
• 13. Parexel International Corporation
• 14. Pfizer Inc.
• 15. VirTrial, LLC by Signant Health